|Articles|August 18, 2003
P&T Portfolio: Xolair
Xolair - Omalizumab should be used as a second-line treatment option for patients with moderate to severe persistent asthma
Advertisement
- Allergy
- Autoimmune Diseases
- Biosimilars
- COVID-19
- Cannabidiol (CBD)
- Cardiology
- Compounding
- Continuous Glucose Monitoring
- Dermatology
- Diabetes
- Digestive Health
- Endocrinology
- Eye Health
- Generics
- HIV
- Headache and Migraine
- Immunization
- Infectious Disease
- Influenza
- Insulin Management
- Medical Devices
- Mental and Behavioral Health
- Neurology
- OTC
- Obesity Management
- Oncology
- Pain Management
- Pediatrics
- Pneumococcal
- Public Health
- Rare Diseases
- Respiratory
- Rheumatology
- Shingles
- Specialty Pharmacy
- Substance Use Disorder
- Technology and Data
- Veterinary Pharmacy
- Women's Health